SALMONELLA

Volver

Resultados 56 resultados LastUpdate Última actualización 23/01/2017 [16:21:00] pdf PDF




Solicitudes publicadas en los últimos 90 días / Applications published in the last 90 days



Página1 de 3 nextPage   Mostrar por página


FLUORESCENT CONJUGATED POLYMERS WITH A BODIPY-BASED BACKBONE AND USES THEREOF

NºPublicación: US2017014532A1 19/01/2017

Solicitante:
UNIV MICHIGAN TECH [US]

Resumen de: US2017014532A1

The present invention provides various fluorescent conjugated polymers with a BODIPY-based backbone. The invention also provides methods of using the polymers of the invention, such as for imaging and detection of cells, tumors, bacteria and viruses.



traducir


 

LIVE ATTENUATED ORAL VACCINE AGAINST SHIGELLOSIS AND TYPHOID FEVER

NºPublicación: WO2017007852A1 12/01/2017

Solicitante:
PROTEIN POTENTIAL LLC [US]

Resumen de: WO2017007852A1

Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.



traducir


 

Multivalent synthetic nanocarrier vaccines

NºPublicación: JP2017008055A 12/01/2017

Resumen de: CN102917731A

The invention relates, at least in part, to compositions comprising populations of synthetic nanocarriers that comprise different sets of antigens as well as related methods.



traducir


 

MUTATED SALMONELLA ENTERIACA

NºPublicación: US2017008935A1 12/01/2017

Solicitante:
THE US SECRETARY OF AGRICULTURE [US]

Resumen de: US2017008935A1

A novel, mutated Salmonella enterica serovar Typhimurium vaccine is generated and imparts protective immunity in vaccinated animals for a range of S. enterica serovars. The vaccine can be attenuated or inactivated, including bacterial ghosts or membrane fractions thereof. Immunogenic compositions are included in the invention and methods of generating an immune response.



traducir


 

POLYSACCHARIDE VACCINE FORMULATIONS AND PROCESSES FOR INDUSTRIAL PRODUCTION OF BACTERIAL POLYSACCHARIDES

NºPublicación: WO2017006349A1 12/01/2017

Solicitante:
BHARAT BIOTECH INT LTD [IN]

Resumen de: WO2017006349A1

The present invention relates to the field of combined vaccine compositions which are effective against all forms of meningococcal diseases as well as typhoid fever. The vaccine formulations comprising antigens from capsular polysaccharides of Neisseria meningitidis A, Neisseria meningitidis C, Neisseria meningitidis Y, Neisseria meningitidis W135, Neisseria meningitidis X, Salmonella typhi Vi capsular polysaccharide (ViPs) or capsular ViPs conjugated to a carrier protein tetanus toxoid (ViPs-TT). This invention is also related to improved methods, especially the use of an improved feed media and an improved method of downstream processing and industrial purification of capsular polysaccharides. The vaccine is free of any animal component or alcohol and is in absolute compliance with respect to the religious sentiments of various ethnic groups. The composition is highly effective and stable, yet cost- effective and affordable, especially for lower-middle income and low-income countries.



traducir


 

A composition and a method for controlling bacterial infection

NºPublicación: GB2540130A 11/01/2017

Solicitante:
INST OF TECH SLIGO [IE]

Resumen de: GB2540130A

A composition for controlling bacterial infection in the gastrointestinal tract of an animal comprising an oxidoreductase enzyme and its corresponding oxidisable substrate which are capable of producing and releasing hydrogen peroxide in the gastrointestinal tract of an animal. Preferably the oxidoreductase enzyme is glucose oxidase. Preferably the oxidisable substrate is D-glucose. The composition may comprise a peroxide of an organic acid, preferably benzoyl peroxide. The composition may comprise L-cysteine. Preferably the composition may be in the form of granules coated with an enteric coating. Also claimed is a method for controlling bacterial infection of meat comprising administration of the composition to an animal for a period of time immediately prior to slaughtering the animal and processing its meat. Preferably the period of time is between 24 and 48 hours immediately before slaughter. Preferably the composition is administered to poultry. The bacterial infection may be caused by Campylobacter spp, Salmonella spp, or Cryptosporidium spp.



traducir


 

METHOD AND DEVICE FOR DETECTION OF PSEUDOMONAS AERUGINOSA

NºPublicación: EP3114483A1 11/01/2017

Solicitante:
YISSUM RES AND DEV COMPANY OF THE HEBREW UNIV OF JERUSALEM LTD [IL]
YEDA RES & DEV [IL]

Resumen de: WO2015132784A1

A method of and device for detecting and diagnosing Pseudomonal aeruginosa in a gaseous, liquid or solid sample, employing Lux-R-like receptor-driven reporter cells.



traducir


 

PHAGE THERAPY OF E COLI INFECTIONS

NºPublicación: US2017000831A1 05/01/2017

Solicitante:
PHERECYDES PHARMA [FR]

Resumen de: US2017000831A1

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.



traducir


 

TOXOID PREPARATION AND USES THEREOF

NºPublicación: US2017000875A1 05/01/2017

Solicitante:
ARYTHA BIOSCIENCES LLC [US]

Resumen de: US2017000875A1

The present invention relates to toxoid preparations comprising a non-disrupted and/or a non-denatured toxin associated with a particulate vector that minimizes or precludes said toxin from inflicting damage at an action site of said toxin. The present invention also relates to immunogenic compositions or vaccines comprising the toxoid preparations, and the methods of using the toxoid preparations, immunogenic compositions or vaccines.



traducir


 

Helicobacter therapeutic

NºPublicación: AU2015283805A1 05/01/2017

Solicitante:
MURDOCH CHILDRENS RES INST

Resumen de: AU2015283805A1

The present invention relates to method of treating and/or preventing inflammation in a subject caused by bacteria that express HtrA. The present invention further relates to immunogenic compositions comprising an HtrA polypeptide or fragment thereof, as well as a therapeutic and/or prophylactic vaccine for treating or preventing disease.



traducir


 

METHODS FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY EXTRACELLULAR MICROORGANISMS, INCLUDING ANTIMICROBIAL-RESISTANT STRAINS THEREOF, USING GALLIUM COMPOUNDS

NºPublicación: US2016375056A1 29/12/2016

Solicitante:
SINAI SCHOOL MEDICINE [US]

Resumen de: US2016375056A1

The present invention relates to methods for preventing or treating infectious diseases caused by extracellular microorganisms, such as bacteria and fungi, by systemically administering to a patient a compound containing gallium. The extracellular microorganisms targeted by the present methods include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), E. coli O157:H7, fluoroquinolone-resistant Salmonella typhi, and the like. Furthermore, in the present methods, gallium compounds can be co-administered with one or more conventional antimicrobial agents to treat infectious diseases with reduced risks of creating multi-drug resistant pathogens. The methods of the present invention is also applicable to those microorganisms, such as ulcer-causing Helicobacter pylori, complete eradication of which so far has been difficult to achieve.



traducir


 

SELECTIVE MEDIA AND USES THEREOF

NºPublicación: WO2016210436A1 29/12/2016

Solicitante:
SABER BIOTICS LLC [US]
OHIO STATE INNOVATION FOUND [US]

Resumen de: WO2016210436A1

The present embodiments provide for media useful for selection and enrichment of Salmonella species. In a particular embodiment, the medium is a minimal medium that includes fructose-asparagine as the sole nutrient source. The fructose-asparagine utilization pathway, particularly FraB, provides a highly selective drug target for inhibiting Salmonella enterica.



traducir


 

ENGINEERED MICROBE-TARGETING MOLECULES AND USES THEREOF

NºPublicación: SG10201608671SA 29/12/2016

Solicitante:
HARVARD COLLEGE [US]

Resumen de: WO2013012924A2

Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface. Microbe-targeting molecules and/or substrates can be regenerated after use by washing with a low pH buffer or buffer in which calcium is insoluble.



traducir


 

PROCEDE D'EVALUTION DU RISQUE DE CONTRACTER LA DIARRHEE DU VOYAGEUR ET TROUSSE POUR LA MISE EN OEUVRE DE CE PROCEDE.

NºPublicación: FR3037656A1 23/12/2016

Solicitante:
PHOENIX CLINICAL RES SAL [LB]

Resumen de: FR3037656A1

L'invention concerne un procédé d'évaluation du risque de contracter la diarrhée du voyageur ou turista. Ce procédé comprend les étapes successives suivantes : - on prélève un échantillon d'un aliment destiné à être ingéré et susceptible de provoquer la diarrhée du voyageur ; et - on met l'échantillon en contact avec un substrat comprenant un matériau test pour la détection de l'agent ou des agents responsable (s) de la diarrhée du voyageur. L'invention se rapporte également à une trousse d'essai ou kit, comprenant au moins : - un dispositif de prélèvement d'échantillon (s) ; et - un substrat comprenant un matériau test pour la détection de l'agent ou des agents responsable (s) de la diarrhée du voyageur. Enfin, l'invention aussi a trait à un appareil d'évaluation du risque de contracter la diarrhée du voyageur.



traducir


 

VEGFR-2 TARGETING DNA VACCINE FOR COMBINATION THERAPY

NºPublicación: WO2016202459A1 22/12/2016

Solicitante:
VAXIMM AG [CH]

Resumen de: WO2016202459A1

The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one further anti-cancer agent. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, wherein the pharmaceutical composition further comprises at least one further attenuated strain of Salmonella comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen or a tumor stroma antigen.



traducir


 

IMMUNOGENIC COMPOSITIONS COMPRISING LAWSONIA INTRACELLULARIS

NºPublicación: US2016367654A1 22/12/2016

Solicitante:
BOEHRINGER INGELHEIM VETMEDICA INC [US]

Resumen de: US2016367654A1

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.



traducir


 

IMMUNOGENIC COMPOSITIONS

NºPublicación: WO2016202872A1 22/12/2016

Solicitante:
GLAXOSMITHKLINE BIOLOGICALS SA [BE]

Resumen de: WO2016202872A1

This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with Shigella strains.



traducir


 

NOVEL CMV PP65 TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY

NºPublicación: WO2016202458A1 22/12/2016

Solicitante:
VAXIMM AG [CH]

Resumen de: WO2016202458A1

The present invention relates to an attenuated strain of Salmonella comprising a DNA molecule encoding CMV pp65. In particular, the present invention relates to the use of said attenuated strain of Salmonella in cancer immunotherapy.



traducir


 

NANOPORE BIOSENSORS FOR DETECTION OF PROTEINS AND NUCLEIC ACIDS

NºPublicación: US2016370358A1 22/12/2016

Solicitante:
KATHOLIEKE UNIV LEUVEN [BE]

Resumen de: US2016370358A1

Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromolecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties.



traducir


 

METHOD AND DEVICE FOR DETECTION OF PSEUDOMONAS AERUGINOSA

NºPublicación: CN106255882A 21/12/2016

Resumen de: WO2015132784A1

A method of and device for detecting and diagnosing Pseudomonal aeruginosa in a gaseous, liquid or solid sample, employing Lux-R-like receptor-driven reporter cells.



traducir


 

ALGAL BASED EDIBLE VACCINES

NºPublicación: EP3104885A1 21/12/2016

Solicitante:
TRANSALGAE (ISRAEL) LTD [IL]

Resumen de: WO2015121863A1

The present invention provides edible vaccines comprising transgenic microalgae expressing at least one exogenous antigen or an intervening organism comprising the transgenic microalgae. The antigen expressing microalgae are used for oral delivery of the antigen to a target organism in its intact and functional form. The exogenous antigen, expressed in the microalgae, is characterized by exerting at least one immunogenic response in the subject consuming the vaccine.



traducir


 

CROSS-PROTECTING SALMONELLA VACCINES

NºPublicación: RU2015119669A 20/12/2016

Resumen de: WO2014064236A1

The present invention discloses that Salmonella enterica serogroup C2-3 serovars cross protect against Salmonella enterica serogroup C1 serovars and vice versa. Therefore, the present invention discloses the use of either a Salmonella enterica serogroup C2-3 serovar or a Salmonella enterica serogroup C1 serovar in the manufacture of a vaccine for administration to poultry to protect against a disorder arising from a Salmonella enterica serogroup C2-3 serovar and/or a disorder arising from a Salmonella enterica serogroup CI serovar.



traducir


 

COMPOSITION FOR ORAL DELIVERY OF BIOACTIVE AGENTS

NºPublicación: JP2016539170A 15/12/2016

Resumen de: WO2015084594A1

A composition for oral administration of a bioactive agent to aquatic or terrestrial species includes particles each of which includes a bioactive agent dispersed in oil droplets, the oil droplets being dispersed in a matrix including an enteric coating polymer, wherein the particles each further include a mucoadhesive polymer. Methods of making and using the composition are also provided.



traducir


 

鸡白痢沙门菌三基因敲除减毒突变株制备及其应用

NºPublicación: CN106222123A 14/12/2016

Resumen de: CN106222123A

本发明属于禽沙门菌病的防治领域,具体涉及种鸡白痢沙门菌三基因敲除减毒突变株制备及其应用。所述减毒株为基因、基因和基因都不表达的鸡白痢沙门菌。本发明通过动物试验发现,所述减毒株毒力显著降低,在宿主体内定殖时间明显缩短,接种后鸡只无不良反应,对强毒力鸡白痢沙门菌提供良好的保护作用,可有效清除强毒力菌株感染。进步的,采用所述减毒株做制备的鸡白痢沙门菌活疫苗,其毒力相对于野生型鸡白痢沙门菌显著降低。接种本发明鸡白痢沙门菌减毒活疫苗后,所述疫苗具有良好的免疫原性,对雏鸡可提供坚实的免疫保护效果。



traducir


 

Shell Egg Pasteurization Processes

Nº publicación: US2016353757A1 08/12/2016

Solicitante:
NAT PASTEURIZED EGGS INC [US]

Resumen de: US2016353757A1

The D-value for pasteurizing chicken shell eggs that are not refrigerated prior to pasteurization, or shell eggs that are sufficiently tempered to room temperature prior to pasteurization, is less than the D-value for pasteurizing chicken shell eggs that are refrigerated prior to pasteurization. Statistically verified time and temperature pasteurization protocols that produce pasteurized chicken shell eggs to achieve at least a statistical 5-log reduction of Salmonella Enteritidis are therefore possible at lower pasteurization temperatures or lower pasteurization dwell times.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver